Literature DB >> 19305147

Functional characterization of p53beta and p53gamma, two isoforms of the tumor suppressor p53.

Vilma Graupner1, Klaus Schulze-Osthoff, Frank Essmann, Reiner U Jänicke.   

Abstract

The p53 gene encodes several isoforms that can interfere with stress responses by modulating p53 wild-type (wt) function. Recently, a C-terminally truncated splice variant, p53beta, has been implicated in the regulation of p53-dependent apoptosis, whereas the function of similarly spliced p53gamma was not investigated before. Therefore, we studied the impact of these isoforms on the function of endogenous p53wt and compared it with that of exogenously expressed p53wt. We demonstrate that despite an efficient nuclear expression of all isoforms, only p53wt modulates apoptosis induction. Furthermore, only p53wt assembles into a transcription-competent oligomeric complex or translocates to mitochondria upon stress induction. Both C-terminally truncated isoforms fail to modulate the apoptotic function of p53wt because they are unable to associate with p53wt and hence do not bind to p53 DNA recognition sequences. Consistently, the dominant-negative function of transactivation-deficient Delta133p53 is completely lost in the Delta133p53beta variant. Intriguingly, the alternatively spliced C-terminus protects p53beta and p53gamma not only from MDM2-mediated proteasomal degradation, but strongly impairs their binding to this negative regulator. Thus, our data demonstrate the necessity of the regularly spliced C-terminal tail for multiple layers of p53 regulation and function.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19305147     DOI: 10.4161/cc.8.8.8251

Source DB:  PubMed          Journal:  Cell Cycle        ISSN: 1551-4005            Impact factor:   4.534


  18 in total

1.  p53 basic C terminus regulates p53 functions through DNA binding modulation of subset of target genes.

Authors:  Pierre-Jacques Hamard; Dana J Lukin; James J Manfredi
Journal:  J Biol Chem       Date:  2012-04-18       Impact factor: 5.157

Review 2.  Dysfunction of the TP53 tumor suppressor gene in lymphoid malignancies.

Authors:  Zijun Y Xu-Monette; L Jeffrey Medeiros; Yong Li; Robert Z Orlowski; Michael Andreeff; Carlos E Bueso-Ramos; Timothy C Greiner; Timothy J McDonnell; Ken H Young
Journal:  Blood       Date:  2012-01-24       Impact factor: 22.113

Review 3.  Senescence regulation by the p53 protein family.

Authors:  Yingjuan Qian; Xinbin Chen
Journal:  Methods Mol Biol       Date:  2013

4.  Differential regulation of the proapoptotic multidomain protein Bak by p53 and p73 at the promoter level.

Authors:  V Graupner; E Alexander; T Overkamp; O Rothfuss; V De Laurenzi; B F Gillissen; P T Daniel; K Schulze-Osthoff; F Essmann
Journal:  Cell Death Differ       Date:  2011-01-14       Impact factor: 15.828

5.  Identification of a DNA Damage-Induced Alternative Splicing Pathway That Regulates p53 and Cellular Senescence Markers.

Authors:  Jing Chen; John Crutchley; Dadong Zhang; Kouros Owzar; Michael B Kastan
Journal:  Cancer Discov       Date:  2017-03-13       Impact factor: 39.397

Review 6.  Translational approaches targeting the p53 pathway for anti-cancer therapy.

Authors:  Frank Essmann; Klaus Schulze-Osthoff
Journal:  Br J Pharmacol       Date:  2012-01       Impact factor: 8.739

7.  p53 Isoforms: An Intracellular Microprocessor?

Authors:  Marie P Khoury; Jean-Christophe Bourdon
Journal:  Genes Cancer       Date:  2011-04

Review 8.  Protein-protein interaction networks: how can a hub protein bind so many different partners?

Authors:  Chung-Jung Tsai; Buyong Ma; Ruth Nussinov
Journal:  Trends Biochem Sci       Date:  2009-12       Impact factor: 13.807

9.  Expression of p53β and Δ133p53 isoforms in different gastric tissues.

Authors:  Wansheng Ji; Na Zhang; Hongmei Zhang; Jingrong Ma; Hua Zhong; Jianxin Jiao; Zhixing Gao
Journal:  Int J Clin Exp Pathol       Date:  2015-09-01

Review 10.  Aberrant splicing of the DMP1-ARF-MDM2-p53 pathway in cancer.

Authors:  Kazushi Inoue; Elizabeth A Fry
Journal:  Int J Cancer       Date:  2016-02-08       Impact factor: 7.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.